Adil Al Lawati

Adil Al Lawati

Auto-generated profile, based on publicly available information

Adil Al Lawati

Division of Nephrology, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Abdullah BalkhairAbdullah Balkhair
Abdullah Balkhair
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
MBM. Al Busaidi
M. Al Busaidi
AAA. Al-Khirbash
A. Al-Khirbash
SMS. Al Mubaihsi
S. Al Mubaihsi
OBO. Balkhair
O. Balkhair
The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were the need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who had received standard treatment and supportive care. A total of 69 patients were included: 45 treated with anakinra and 24 historical controls. A need for mechanical ventilation occurred in 14 (31%) of the anakinra-treated group and 18 (75%) of the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) of the anakinra-treated group and 11 (46%) of the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) of the anakinra-treated group compared with 6 (27%) of the historical cohort (p = 0.008). Patients who received anakinra showed a significant reduction in inflammatory biomarkers. In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit. ISRCTN74727214.

1 January 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FKFaryal khamis
Faryal khamis
HNHanan Al Naabi
Hanan Al Naabi
ALAdil Al Lawati
Adil Al Lawati
ZAZaiyana Ambusaidi
Zaiyana Ambusaidi
MSMariam Al Sharji
Mariam Al Sharji
IAIbrahim Al-Zakwani
Ibrahim Al-Zakwani
To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted. Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (HCQ). The outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality. A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned HCQ. The overall mean age was 55 ± 14 years and 58% (n = 52) were males. There were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410). There were also no significant differences between the two groups with regards to the overall LOS (7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p = 0.764) and overall mortality (11.4% vs 13.3%; p = 0.778). No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.

1 July 2026 in JBJS Case Connector
Verified
Journal Article
Closed access
DADalia Abdel-Hadi
Dalia Abdel-Hadi
ALAli Al Lawati
Ali Al Lawati
AFAhmed Al Farkani
Ahmed Al Farkani
YBYahya Al Badaai
Yahya Al Badaai
HFHumaid Al Farii
Humaid Al Farii
Case: A 32-year-old man with end-stage renal disease (ESRD) from anti-neutrophil cytoplasmic antibody-associated vasculitis and tertiary hyperparathyroidism, presented with progressive right hip pain. A giant cell-rich lesion biopsy confirmed Brown tumor. Despite cinacalcet and vitamin D, hyperparathyroidism persisted, necessitating parathyroidectomy complicated by hungry bone syndrome and a pathological right hip fracture. Surgical fixation and prosthetic replacement were deferred due to high risk factors such as, ESRD and fracture pattern, as well as potential for postoperative implant failure and infection. Teriparatide was initiated to promote bone remodeling, leading to pain relief and radiographic improvement. Conclusion: To our knowledge, this is the first reported long-bone Brown tumor successfully treated with teriparatide.